Microneedle-based delivery of PEGylated nanoparticles triggers the production of anti-PEG antibodies
RSC Pharmaceutics · 2026 · 3 (6) · 1540-1549
DOI: 10.1039/d6pm00143b ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Sabrina Roussel und 3 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research, Canada Foundation for Innovation.
Abstract (Originalsprache)
Polyethylene glycol- b -polylactic acid (PEG–PLA) nanoparticles were incorporated into polyvinylpyrrolidone/polyvinyl alcohol (PVP/PVA) microneedles. When injected intradermally, the nanoparticles triggered the production of anti-PEG IgM antibodies.
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
- Canada Foundation for Innovation
- Fonds de Recherche du Québec - Santé
- Université Laval
- Fondation CHU de Québec
Zitieren
APA
Roussel, S., Ates, E., Donnelly, R. F., & Bertrand, N. (2026). Microneedle-based delivery of PEGylated nanoparticles triggers the production of anti-PEG antibodies. RSC Pharmaceutics, 3(6), 1540-1549. https://doi.org/10.1039/d6pm00143b
Vancouver
Roussel S, Ates E, Donnelly RF, Bertrand N. Microneedle-based delivery of PEGylated nanoparticles triggers the production of anti-PEG antibodies. RSC Pharmaceutics. 2026;3(6):1540-1549. doi:10.1039/d6pm00143b
BibTeX
@article{Roussel2026,
author = {Roussel, Sabrina and Ates, Ece and Donnelly, Ryan F. and Bertrand, Nicolas},
title = {Microneedle-based delivery of PEGylated nanoparticles triggers the production of anti-PEG antibodies},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {6},
pages = {1540--1549},
doi = {10.1039/d6pm00143b}
}
EUVIMED